Abstract
In late 1989, an epidemic of eosinophilia-myalgia syndrome (EMS) that resulted in several thousand cases of the syndrome and 36 deaths was recognized in the United States. Physicians in New Mexico linked the epidemic to the ingestion of L-tryptophan (LT). Results of studies indicated that one or more trace contaminants in LT were likely causes of the EMS epidemic. Investigators traced the LT that was taken by most patients with EMS to a single manufacturer, Showa Denko K.K. of Japan.
We now report results of high performance liquid chromatographic analysis of LT samples from this manufacturer. Three sets of blind-coded samples were analyzed: the priority case lot set, which included 54 case-associated LT lots and 50 noncase-associated LT lots that were taken by case and control subjects who used only one brand of LT; the single lot case set, which included 73 case-associated LT lots and 25 noncase associated LT lots taken by case and control subjects who used only a single lot of LT; and the South Carolina tablet set, which included LT tablets taken by case subjects (n=26) and by control subjects (n=52). We statistically compared the concentration of each contaminant in case-associated, noncase-associated, and control samples of each sample set. The analyses showed that there were more than 60 minor contaminants in the LT from Showa Denko K.K., and that six of these contaminants were associated with EMS. The structures of three contaminants are known, but the identities of the other three contaminants are currently unknown. In this paper, we discuss each sample set and results of the analysis of each, the combined results of all sets, the identity of the six contaminants, and implications for future research into the etiology of EMS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barnhart ER, Maggio VL, Alexander LR, Turner WE, Patterson DG, Needham LL, Reilly MH, Gelbaum LT (1990) Bacitracin-associated peptides and contaminated L-tryptophan. Lancet ii:742.
Belongia EA, Hedberg CW, Gleich GJ, White KE, Mayeno AN, Loegering DA, Dunnette SL, Pirie PL, MacDonald KL, Osterholm MT (1990) An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 323:357–365
Caudill SP, Hill RH, Kamb ML, Philen R, Bailey SL, Gregg M, Needham LL (1992) Important issues affecting eosinophilia-myalgia syndrome investigations based on analyses of L-tryptophan samples. Int J Occup Med Toxicol (in press)
Centers for Disease Control (1989a) Eosinophilia-myalgia syndrome—New Mexico. Morb Mort Wkly Rep 38:765–767
--(1989b) Eosinophilia-myalgia syndrome and L-tryptophan-containing products—New Mexico, Minnesota, Oregon, and New York, 1989. Morb Mort Wkly Rep 38:785–788
--(1990a) Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome, Morb Mort Wkly Rep 39:589–591
--(1990b) Update: analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome, Morb Mort Wkly Rep 39:789–790
Clauw DJ, Nashel DJ, Umhau A, and Katz P (1990) Tryptophan-associated eosinophilic connective-tissue disease. J Am Med Assoc 263:502–506
Crofford LJ, Rader JI, Dalakas MC, Hill RH, Page SW, Needham LL, Brady LS, Heyes MP, Wilder RL, Gold PW, Illa I, Smith C, Sternberg EM (1990) L-Tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest 86:1757–1763
Fisher RA (1958) Statistical methods for research workers. Hafner Publishing Co, Inc, NY, pp 100–101
Goda Y, Suzuki J, Maitani T, Yoshihira K, Takeda M, Uchiyama M (1992) Anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples, Chem Pharmacol Bull (Japan) 40:2236–2238
Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich G (1990) Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 332:869–873
Kamb ML, Murphy JJ, Jones JL, Caston JC, Nederlof K, Horney LF, Sweygert LA, Falk H, Kilbourne EM (1992) Eosinophilia-myalgia syndrome in L-tryptophan exposed patients in a South Carolina psychiatric practice. J Am Med Assoc 267:77–82
Kleinbaum DG, Kupper LL, Mortgenstern H (1982) Epidemiologic Research. Lifetime Learning Publications, Belmont, CA, pp 419–446
Koziol JA (1989) A note on plots of p-values to evaluate many tests simultaneously. Biom J 31:969–972
Love LA, Rader JI, Crofford LJ, Page SW, Hill RH, Raybourne RB, Sternberg EM (1991) L-Tryptophan (L-TRP) and 1,1′-ethylidenebis[tryptophan] (EBT), a contaminant in eosinophilia-myalgia syndrome (EMS) case-associated L-TRP, cause myofascial thickening and pancreatic fibrosis in Lewis rats. Arth Rheum (Supplement) 34:S131
Mann HB, Whitney DR (1947) On a test of whether one of two random variables is statistically larger than the other. Ann Math Stat 18:50–60
Mayeno AN, Lin F, Foote CS, Loegering DA, Ames MW, Hedberg CW, Gleich GJ (1990) Characterization of “peak E,” a novel amino acid associated with eosinophilia-myalgia syndrome. Science 250:1707–1708
Miller RG (1981) Simultaneous statistical inference. Springer-Verlag, NY, pp 67–68
Müller A, Busker E, Gunther K, Hoppe B (1991) Characterization of byproducts in L-tryptophan, Bioforum 14:350–354
Philen RM, Hill RH, Flanders WD, Caudill SP, Needham LL, Sewell L, Sampson EJ, Falk H, Kilbourne EM, Oregon, New York, New Mexico EMS study groups. (1992) Tryptophan contaminants associated with eosinophilia-myalgia syndrome. Am J Epidemiol (submitted in September 1992)
Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM (1990) Scleroderma, fascitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 332:874–881
Slutsker L, Hoesly FC, Miller L, Williams P, Watson JC, Fleming DW (1990) Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. J Am Med Assoc 264:213–217
Smith MJ, Mazzola EP, Farrell TJ, Sphon JA, Page SW, Ashley D, Sirimanne SR, Hill RH, and Needham LL (1991) 1,1′-Ethylidenebis(L-tryptophan), structure determination of contaminant “97”—implicated in the eosinophilia-myalgia syndrome (EMS). Tetrahedron Lett 32:991–994
Schweder T, Spjotvoll E (1982) Plots of p-values to evaluate many tests simultaneously. Biometrika 69:493–502
Toyooka T, Yamazaki T, Tanimoto T, Sato M, Toyoda M, Ishibashi M, Yoshihira K, Uchiyama M (1991) Characterization of contaminants in EMS-associated L-tyrptophan samples by high-performance liquid chromatography. Chem Pharmacol Bull (Jpn) 39:820–822
World Health Organization (1991) Toxic oil syndrome and eosinophilia-myalgia syndrome: pursuing parallels in pathogenesis, report on a WHO meeting, May 8–10, 1991, Washington, D.C. WHO Regional Office for Europe, Target 22, World Health Organization, Copenhagen, Denmark
— (1992) Toxic oil syndrome: current knowledge and future perspectives. WHO Regional Publications, European Series, No. 42, World Health Organization, Copenhagen, Denmark
Author information
Authors and Affiliations
Additional information
Use of trade names is for identification only and does not contitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services.
Rights and permissions
About this article
Cite this article
Hill, R.H., Caudill, S.P., Philen, R.M. et al. Contaminants in L-Tryptophan associated with eosinophilia myalgia syndrome. Arch. Environ. Contam. Toxicol. 25, 134–142 (1993). https://doi.org/10.1007/BF00230724
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00230724